<DOC>
	<DOCNO>NCT02253875</DOCNO>
	<brief_summary>Study determine effect multiple-dose omeprazole single-dose pharmacokinetics tipranavir ritonavir</brief_summary>
	<brief_title>Study Determine Effects Multiple-dose Omeprazole Single-dose Pharmacokinetics Tipranavir ( TPV ) Coadministered With Ritonavir ( RTV ) Healthy Adult Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Tipranavir</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<criteria>1 . Male female healthy volunteer 18 60 year age inclusive 2 . Clinically normal medical history 3 . Clinically normal finding physical examination 4 . Clinically normal laboratory value 5 . Body Mass Index ( BMI ) 18.5 30 kg/m2 inclusive 6 . Ability swallow large capsule without difficulty 7 . Capable comprehend communicate effectively investigator site staff 8 . Signed date write informed consent form , accordance Ethics Committee regulatory guideline prior trial participation 9 . Willingness abstain ingest substance may alter plasma drug level interaction cytochrome P450 system 14 day study 10 . Willingness abstain alcohol 48 hour prior Visit 2 duration study 11 . Willingness abstain ingest grapefruit grapefruit juice 7 day Visit 2 duration study 12 . Negative pregnancy test ( βhCG ) 13 . Negative HIV serology 14 . Negative hepatitis serology 1 . Any clinically significant disease ( significant disease define disease , opinion investigator may either put subject risk participation study , disease may influence result study subject 's ability participate study ) 2 . Clinically significant abnormal baseline hematology , blood chemistry urinalysis finding normal Visit 2 3 . Serum Alanine Aminotransferase ( ALT ) , Aspartate Aminotransferase ( AST ) , cholesterol , triglyceride glucose great upper limit normal Visit 2 4 . Treatment investigational drug within 90 day prior first dose study medication 5 . Inability adhere requirement protocol assessed investigator 6 . Prior TPV use 7 . Subjects take take medication metabolize Cytochrome P450 ( CYP450 ) enzyme system within 30 day prior Visit 2 8 . Subject seat systolic blood pressure either &lt; 100 mmHg &gt; 150 mmHg ; rest heart rate either &lt; 50 beats/min &gt; 100 beats/min 9 . Subject history illness allergy investigator opinion might confound result study , pose additional risk subject administer TPV/r omeprazole 10 . Subject acute illness within 14 day prior Visit 2 11 . Subject currently take take overthecounter medication 14 day prior Visit 2 , subject currently take prescription medication 12 . Known hypersensitivity TPV , RTV , omeprazole antiretroviral drug ( market experimental use part clinical research study ) 13 . Female subject reproductive potential : Pregnant breastfeeding Have positive serum βhCG ( pregnancy test ) screen visit ( Visit 1 ) Have use barrier contraceptive method least 60 day prior Study Day 1 Are willing use reliable method doublebarrier contraception trial 30 day completion termination trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>